ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

ECOG-ACRIN 胸部恶性肿瘤综合转化科学中心

基本信息

批准号：
10582677
负责人：
DAVID P. CARBONE
金额：
$ 62.16万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-14 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10582677
关键词：
American College of Radiology Imaging Network Area Award BRAF gene Biological Markers Center for Translational Science Activities Chest Clinical Clinical Data Clinical Sciences Clinical Trials Clinical Trials Network Collaborations Combined Modality Therapy Detection Development Disease EGFR inhibition Early Diagnosis Eastern Cooperative Oncology Group Enrollment Epidermal Growth Factor Receptor Excision Funding Genomics Goals Grant Immunologic Markers Immunotherapy Institution Leadership Lung Lung Neoplasms Malignant neoplasm of lung Malignant neoplasm of thorax Molecular Molecular Abnormality Molecular Analysis Mutation National Clinical Trials Network Non-Small-Cell Lung Carcinoma Operative Surgical Procedures Patient-Focused Outcomes Patients Pilot Projects Plasma Plasma Cells Play Poly(ADP-ribose) Polymerase Inhibitor Precision Medicine Initiative Precision therapeutics Prevention Process Proteomics ROS1 gene Recurrence Research Research Personnel Residual Neoplasm Resistance Role STK11 gene Science Selection for Treatments Specimen Technology Testing Time Translational Research Work biomarker development biomarker discovery biomarker driven biomarker evaluation cell free DNA checkpoint inhibition chemotherapy clinical care cohort companion diagnostics driver mutation drug development epigenetic marker epigenomics improved improved outcome innovation lung cancer screening next generation novel novel marker novel strategies personalized medicine phase 3 study programmed cell death ligand 1 programs prospective risk prediction risk stratification small cell lung carcinoma targeted agent targeted treatment tumor

项目摘要

PROJECT SUMMARY/ABSTRACT The ECOG-ACRIN Thoracic Integrated Translational Research Center (EA-ITSC) comprises a team of accomplished researchers with a proven track record of collaborative work to improve outcomes for patients with lung cancer. The EA-ITSC, funded in 2014 by the NCI (U10) at the same time as the formation of the National Clinical Trials Network (NCTN), has played a major role in developing novel approaches for risk stratification, molecular testing, and treatment of lung cancer. This group has also been responsible for guiding the development of biomarker-driven clinical trials initiated by the ECOG-ACRIN Thoracic Malignancies Committee. Our highly collaborative team approach includes sharing specimens across institutions, conducting pilot projects that are of direct relevance to NCTN trials and guiding the translational research components of all newly developed ECOG-ACRIN thoracic malignancies trials. Our overarching goal is to develop novel biomarkers to enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination treatment approaches to enhance the efficacy of existing therapies in lung cancer within the context of the NCTN. With this application, we propose to continue our research work with direct relevance to the NCTN, with the following specific aims: 1) To develop genomic, epigenomic, and proteomics approaches to enhance biomarker discovery efforts in ongoing and planned ECOG-ACRIN studies; 2) To conduct pilot studies on existing ECOG- ACRIN and institutional lung cancer tumor specimens that will lead to prospective NCTN clinical trials; and 3) To guide the development of translational research components of ECOG-ACRIN Thoracic trials and promote collaborations with lung cancer SPORE and P01 institutions. The EA-ITSC will have a robust pilot projects program from years 2-6 of this award that will invite participation from all the NCTN network groups, institutions with lung cancer SPORE and P01 awards, to bring the best science to NCTN clinical trials.

项目概要/摘要 ECOG-ACRIN 胸部综合转化研究中心 (EA-ITSC) 由以下团队组成：成就卓著的研究人员在改善患有以下疾病的患者的治疗效果方面拥有良好的合作记录肺癌。 EA-ITSC 于 2014 年由 NCI (U10) 资助，同时成立了国家临床试验网络 (NCTN) 在开发新的风险分层方法方面发挥了重要作用，分子检测和肺癌治疗。该小组还负责指导由 ECOG-ACRIN 胸部恶性肿瘤委员会发起的生物标志物驱动的临床试验的开发。我们高度协作的团队方法包括跨机构共享标本、开展试点项目与 NCTN 试验直接相关，并指导所有新试验的转化研究部分开发了 ECOG-ACRIN 胸部恶性肿瘤试验。我们的首要目标是开发新型生物标志物增强免疫疗法的功效，克服对靶向药物的耐药性并确定组合在 NCTN 背景下增强现有肺癌疗法疗效的治疗方法。通过此申请，我们建议继续与 NCTN 直接相关的研究工作，以下具体目标： 1) 开发基因组学、表观基因组学和蛋白质组学方法来增强生物标志物正在进行和计划中的 ECOG-ACRIN 研究中的发现工作； 2) 对现有的ECOG-进行试点研究 ACRIN 和机构肺癌肿瘤标本将导致前瞻性 NCTN 临床试验； 3) 至指导 ECOG-ACRIN 胸部试验转化研究部分的开发并促进与肺癌SPORE和P01机构合作。 EA-ITSC 将拥有强大的试点项目该奖项第 2-6 年的计划将邀请所有 NCTN 网络团体、机构参与荣获肺癌 SPORE 和 P01 奖项，将最好的科学带入 NCTN 临床试验。